Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.

Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Idbaih A, Lemare F, de Botton S, Sanson M, Touat M.

Neuro Oncol. 2020 Mar 26. pii: noaa074. doi: 10.1093/neuonc/noaa074. [Epub ahead of print] No abstract available.

PMID:
32215616
2.

High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.

Roux A, Pallud J, Saffroy R, Edjlali-Goujon M, Debily MA, Boddaert N, Sanson M, Puget S, Knafo S, Adam C, Faillot T, Cazals-Hatem D, Mandonnet E, Polivka M, Dorfmüller G, Dauta A, Desplanques M, Gareton A, Pages M, Tauziede-Espariat A, Grill J, Bourdeaut F, Doz F, Dhermain F, Mokhtari K, Chretien F, Figarella-Branger D, Varlet P.

Neuro Oncol. 2020 Feb 6. pii: noaa024. doi: 10.1093/neuonc/noaa024. [Epub ahead of print]

PMID:
32025728
3.

Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.

Roux A, Tauziede-Espariat A, Zanello M, Peeters S, Zah-Bi G, Parraga E, Edjlali M, Lechapt E, Shor N, Bellu L, Berzero G, Dormont D, Dezamis E, Chretien F, Oppenheim C, Sanson M, Varlet P, Capelle L, Dhermain F, Pallud J.

Neuro Oncol. 2020 Feb 6. pii: noaa022. doi: 10.1093/neuonc/noaa022. [Epub ahead of print]

PMID:
32025725
4.

Strain-Dependent Effect of Capsule on Transmission and Persistence in an Infant Mouse Model of Group A Streptococcus Infection.

Vega LA, Sanson MA, Shah BJ, Flores AR.

Infect Immun. 2020 Mar 23;88(4). pii: e00709-19. doi: 10.1128/IAI.00709-19. Print 2020 Mar 23.

PMID:
32014891
5.

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL.

Clin Cancer Res. 2020 Feb 1;26(3):552-557. doi: 10.1158/1078-0432.CCR-19-2109. Epub 2020 Jan 22.

PMID:
31969329
6.

Pseudo-continuous arterial spin labelling shows high diagnostic performance in the detection of postoperative residual lesion in hyper-vascularised adult brain tumours.

Cohen C, Law-Ye B, Dormont D, Leclercq D, Capelle L, Sanson M, Galanaud D, Pyatigorskaya N.

Eur Radiol. 2020 Jan 21. doi: 10.1007/s00330-019-06474-4. [Epub ahead of print]

PMID:
31965259
7.

Lobophora (Dictyotales) Species Richness, Ecology and Biogeography Across the North-Eastern Atlantic Archipelagos and Description of Two New Species1.

Vieira C, Henriques F, D'hondt S, Neto A, Almada CH, Kaufmann M, Sansón M, Sangil C, Clerck O.

J Phycol. 2019 Dec 18. doi: 10.1111/jpy.12956. [Epub ahead of print]

PMID:
31849038
8.

Unexpected relationships between frequency of antimicrobial resistance, disease phenotype and emm type in group A Streptococcus.

Sanson MA, Macias OR, Shah BJ, Hanson B, Vega LA, Alamarat Z, Flores AR.

Microb Genom. 2019 Nov;5(11). doi: 10.1099/mgen.0.000316.

9.

Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.

Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ.

J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19.

PMID:
31743054
10.

EGFR gene amplification in monocentric and multicentric glioblastoma.

Nichelli L, Dormont D, Sanson M, Di Stefano AL.

J Neurooncol. 2019 Dec;145(3):587-589. doi: 10.1007/s11060-019-03324-7. Epub 2019 Nov 15. No abstract available.

PMID:
31728885
11.

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Grandin N, Pereira B, Cohen C, Billard P, Dehais C, Carpentier C, Idbaih A, Bielle F, Ducray F, Figarella-Branger D, Delattre JY, Sanson M, Lomonte P, Poncet D, Verrelle P, Charbonneau M; POLA network.

Acta Neuropathol Commun. 2019 Nov 9;7(1):175. doi: 10.1186/s40478-019-0833-0.

12.

Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.

Trisolini E, Wardighi DE, Giry M, Bernardi P, Boldorini RL, Mokhtari K, Sanson M.

J Neurooncol. 2019 Nov;145(2):241-245. doi: 10.1007/s11060-019-03306-9. Epub 2019 Oct 31.

PMID:
31673897
13.

Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis.

Saunders CN, Cornish AJ, Kinnersley B, Law PJ, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

Neuro Oncol. 2020 Feb 20;22(2):207-215. doi: 10.1093/neuonc/noz209.

PMID:
31665421
14.

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H; Lifelines Cohort authors, Christen T, Mook-Kanamori DO; ICBP Consortium, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S; METASTROKE Consortium of the ISGC, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD.

BMC Cardiovasc Disord. 2019 Oct 29;19(1):240. doi: 10.1186/s12872-019-1187-z.

15.

Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.

Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G.

Brain Pathol. 2019 Sep 27. doi: 10.1111/bpa.12788. [Epub ahead of print]

PMID:
31561286
16.

Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma.

Lahmi L, Idbaih A, Rivin Del Campo E, Hoang-Xuan K, Mokhtari K, Sanson M, Canova CH, Carpentier A, Jacob J, Maingon P, Feuvret L.

J Clin Neurosci. 2019 Oct;68:39-44. doi: 10.1016/j.jocn.2019.07.065. Epub 2019 Aug 6.

PMID:
31399318
17.

Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Boisseau W, Euskirchen P, Mokhtari K, Dehais C, Touat M, Hoang-Xuan K, Sanson M, Capelle L, Nouet A, Karachi C, Bielle F, Guégan J, Marie Y, Martin-Duverneuil N, Taillandier L, Rousseau A, Delattre JY, Idbaih A.

Oncologist. 2019 Dec;24(12):1584-1592. doi: 10.1634/theoncologist.2019-0223. Epub 2019 Jul 25.

18.

Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A.

J Neurooncol. 2019 Aug;144(1):33-41. doi: 10.1007/s11060-019-03204-0. Epub 2019 Jun 13.

19.

Evidence That "Voluntary" Versus "Involuntary" Retrieval Is a Fluency-Based Attribution.

Sanson M, Cardwell BA, Rasmussen AS, Garry M.

Psychol Rep. 2020 Feb;123(1):141-158. doi: 10.1177/0033294119854180. Epub 2019 Jun 3. No abstract available.

PMID:
31159670
20.

In vivo 1 H MRS detection of cystathionine in human brain tumors.

Branzoli F, Deelchand DK, Sanson M, Lehéricy S, Marjańska M.

Magn Reson Med. 2019 Oct;82(4):1259-1265. doi: 10.1002/mrm.27810. Epub 2019 May 26.

PMID:
31131476
21.

Publisher Correction: Mendelian randomisation study of the relationship between vitamin D and risk of glioma.

Takahashi H, Cornish AJ, Sud A, Law PJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Turnbull C, Houlston RS.

Sci Rep. 2019 May 23;9(1):7924. doi: 10.1038/s41598-019-43787-2.

22.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
23.

Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.

PMID:
30890548
24.

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

Branzoli F, Pontoizeau C, Tchara L, Di Stefano AL, Kamoun A, Deelchand DK, Valabrègue R, Lehéricy S, Sanson M, Ottolenghi C, Marjańska M.

Neuro Oncol. 2019 Jun 10;21(6):765-774. doi: 10.1093/neuonc/noz031.

PMID:
30726924
25.

Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma.

Atkins I, Kinnersley B, Ostrom QT, Labreche K, Il'yasova D, Armstrong GN, Eckel-Passow JE, Schoemaker MJ, Nöthen MM, Barnholtz-Sloan JS, Swerdlow AJ, Simon M, Rajaraman P, Chanock SJ, Shildkraut J, Bernstein JL, Hoffmann P, Jöckel KH, Lai RK, Claus EB, Olson SH, Johansen C, Wrensch MR, Melin B, Jenkins RB, Sanson M, Bondy ML, Houlston RS.

Cancer Res. 2019 Apr 15;79(8):2065-2071. doi: 10.1158/0008-5472.CAN-18-2888. Epub 2019 Feb 1.

26.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

27.

Developmental venous anomaly in adult patients with diffuse glioma: A clinically relevant coexistence?

Roux A, Edjlali M, Porelli S, Tauziede-Espariat A, Zanello M, Dezamis E, Zah-Bi G, Sanson M, Puget S, Capelle L, Varlet P, Oppenheim C, Pallud J.

Neurology. 2019 Jan 1;92(1):e55-e62. doi: 10.1212/WNL.0000000000006690. Epub 2018 Nov 30.

PMID:
30504430
28.

The clinical use of IDH1 and IDH2 mutations in gliomas.

Picca A, Berzero G, Di Stefano AL, Sanson M.

Expert Rev Mol Diagn. 2018 Dec;18(12):1041-1051. doi: 10.1080/14737159.2018.1548935. Epub 2018 Nov 29. Review.

29.

Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.

Picca A, Di Stefano AL, Sanson M.

Curr Opin Neurol. 2018 Dec;31(6):727-732. doi: 10.1097/WCO.0000000000000617. Review.

PMID:
30239358
30.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
31.

Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.

Morisse MC, Jouannet S, Dominguez-Villar M, Sanson M, Idbaih A.

Expert Rev Neurother. 2018 Sep;18(9):729-737. doi: 10.1080/14737175.2018.1510321. Epub 2018 Aug 22. Review.

PMID:
30099909
32.

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, Sanson M.

Nat Commun. 2018 Jun 18;9(1):2371. doi: 10.1038/s41467-018-04622-w.

33.

Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.

Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, Sanson M, Delattre JY, Honnorat J, Desestret V, Alentorn A.

Br J Cancer. 2018 Jul;119(1):105-113. doi: 10.1038/s41416-018-0125-7. Epub 2018 Jun 14.

34.

FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.

PMID:
29728520
35.

Pazopanib efficacy in recurrent central nervous system hemangiopericytomas.

Apra C, Alentorn A, Mokhtari K, Kalamarides M, Sanson M.

J Neurooncol. 2018 Sep;139(2):369-372. doi: 10.1007/s11060-018-2870-0. Epub 2018 Apr 26.

36.

Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.

PMID:
29549621
37.

Impact of atopy on risk of glioma: a Mendelian randomisation study.

Disney-Hogg L, Cornish AJ, Sud A, Law PJ, Kinnersley B, Jacobs DI, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

BMC Med. 2018 Mar 15;16(1):42. doi: 10.1186/s12916-018-1027-5.

38.

Influence of obesity-related risk factors in the aetiology of glioma.

Disney-Hogg L, Sud A, Law PJ, Cornish AJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Swerdlow AJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

Br J Cancer. 2018 Apr;118(7):1020-1027. doi: 10.1038/s41416-018-0009-x. Epub 2018 Mar 13.

39.

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.

PMID:
29520610
40.

Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.

Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19.

41.

Current therapeutic approaches to diffuse grade II and III gliomas.

Picca A, Berzero G, Sanson M.

Ther Adv Neurol Disord. 2018 Jan 17;11:1756285617752039. doi: 10.1177/1756285617752039. eCollection 2018.

42.

Mendelian randomisation study of the relationship between vitamin D and risk of glioma.

Takahashi H, Cornish AJ, Sud A, Law PJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Turnbull C, Houlston RS.

Sci Rep. 2018 Feb 5;8(1):2339. doi: 10.1038/s41598-018-20844-w. Erratum in: Sci Rep. 2019 May 23;9(1):7924.

43.

SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook.

Reznik Y, Barat P, Bertherat J, Bouvattier C, Castinetti F, Chabre O, Chanson P, Cortet C, Delemer B, Goichot B, Gruson D, Guignat L, Proust-Lemoine E, Sanson MR, Reynaud R, Boustani DS, Simon D, Tabarin A, Zenaty D.

Ann Endocrinol (Paris). 2018 Feb;79(1):1-22. doi: 10.1016/j.ando.2017.12.001. Epub 2018 Jan 12.

44.

A metabolic function of FGFR3-TACC3 gene fusions in cancer.

Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, Sanson H, Frederick V, Castano AM, Cerulo L, Rolland DCM, Mall R, Mokhtari K, Elenitoba-Johnson KSJ, Sanson M, Huang X, Ceccarelli M, Lasorella A, Iavarone A.

Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.

45.

Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.

Ibañez-Juliá MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, Louis S, Balaguer A, Sanson M, Le Guern E, Latour P, Ricard D, Stojkovic T, Psimaras D.

Acta Oncol. 2018 Mar;57(3):403-411. doi: 10.1080/0284186X.2017.1415462. Epub 2017 Dec 15.

PMID:
29243538
46.

Progestin-associated shift of meningioma mutational landscape.

Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L, Raffin-Sanson ML, Sanson M, Kalamarides M.

Ann Oncol. 2018 Mar 1;29(3):681-686. doi: 10.1093/annonc/mdx763.

47.

Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.

Branzoli F, Di Stefano AL, Capelle L, Ottolenghi C, Valabrègue R, Deelchand DK, Bielle F, Villa C, Baussart B, Lehéricy S, Sanson M, Marjanska M.

Neuro Oncol. 2018 Jun 18;20(7):907-916. doi: 10.1093/neuonc/nox214.

48.

Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.

Bielle F, Di Stefano AL, Meyronet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D, Maurage CA, Uro-Coste E, Lasorella A, Iavarone A, Sanson M, Mokhtari K.

Brain Pathol. 2018 Sep;28(5):674-683. doi: 10.1111/bpa.12563. Epub 2017 Nov 21.

PMID:
28976058
49.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

50.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

Supplemental Content

Loading ...
Support Center